SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Nulojix

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2011.
Why 3/10
Nulojix is an already-approved, marketed drug with no pending regulatory decision (PDUFA, AdComm, or pivotal readout) scheduled in the next 12 months. It is a niche product grouped under "Other Growth Brands" within BMS's $48B+ annual revenue, and BMS does not break out its revenue. Therefore, impactScore is 3 per the rubric: approved and commercializing with no binary catalyst, a small part of a large pipeline.
Actionable Insight NEUTRAL

Nulojix has no scheduled PDUFA dates, AdComms, or pivotal readouts in the next 12 months. Watch for any label expansion into pediatric kidney transplant or heart transplant (Phase 2 data ongoing), but neither represents a near-term binary event. The main long-term risk is biosimilar entry as patents expire, with Alphamab Oncology's KN019 (belatacept biosimilar) in Chinese clinical development.

Price Chart

Loading chart...

Executive Summary

Nulojix (belatacept) is an FDA-approved biologic from Bristol Myers Squibb (BMY) used to prevent organ rejection in adult kidney transplant recipients. Approved in June 2011, it is a selective T-cell costimulation blocker that offers a kidney-friendly alternative to calcineurin inhibitors. However, Nulojix is a niche product within BMS's massive $48B+ annual revenue base; the company does not break out its revenue separately, grouping it under "Other Growth Brands." With no pending regulatory decisions or near-term pivotal readouts, Nulojix is a mature, commercial-stage asset with limited binary catalyst potential for BMY shares.

How It Works

Nulojix is a biologic drug (a lab-made protein) that suppresses the immune system to prevent the body from attacking a transplanted kidney. It works by blocking a key activation signal that T-cells (a type of white blood cell) need to launch an immune response against the donor organ. This makes it an alternative to older immunosuppressants that can damage the kidneys over time.

Trial Status

Nulojix was approved by the FDA in June 2011 based on two Phase 3 trials (BENEFIT and BENEFIT-EXT) comparing it to cyclosporine in adult kidney transplant recipients. It is a marketed product. A Phase 2 investigator-sponsored trial (NCT06478017) is evaluating belatacept in heart transplantation, and pediatric data have been published in medical journals, but no pivotal registrational trials for label expansion are currently listed.

The Two-Sided Case

▲ Bull Case3
Nulojix offers a kidney-sparing alternative to calcineurin inhibitors, a meaningful clinical advantage that supports steady adoption at transplant centers.
No approved biosimilar exists as of 2026, providing continued market exclusivity for BMS.
Published pediatric data and an ongoing Phase 2 heart transplant trial suggest potential for future label expansion into broader transplant populations.
▼ Bear Case4
Nulojix is a niche product with un-disclosed revenue buried in BMS's 'Other Growth Brands' category, meaning it has negligible impact on BMY's overall financials.
The drug carries a boxed warning for post-transplant lymphoproliferative disorder (PTLD) and is contraindicated in EBV-seronegative patients, limiting its addressable market.
Biosimilar competition is emerging (Alphamab's KN019 in China), and eventual patent expiration will erode what modest revenue the drug generates.
BMS faces broader headwinds from patent cliffs on larger drugs (Eliquis, Opdivo), making a niche product like Nulojix immaterial to the investment thesis.

Upcoming Catalysts

  • No scheduled PDUFA dates or pivotal readouts for Nulojix in the next 12 months.
  • Ongoing Phase 2 heart transplant data (NCT06478017) could inform future label expansion but is not a near-term binary catalyst.
  • Biosimilar competition: Alphamab Oncology's KN019 (belatacept biosimilar) is in clinical development in China but not yet filed in the US.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 drugs.com3 news.bms.com4 accessdata.fda.gov5 biocosm.io6 drugpatentwatch.com7 drugpatentwatch.com8 alphamabonc.com9 bms.com10 clinicaltrials.gov11 packageinserts.bms.com12 bms.com